Business
Enlivex Announces New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annual Meeting
Stand-alone therapy with PD1 checkpoint inhibitors has shown limited efficacy against ovarian cancer, with response rates in prior clincical trials ranging
About this update from Enlivex Ltd.
[{"type":"text","content":"Stand-alone therapy with PD1 checkpoint inhibitors has shown limited efficacy against ovarian cancer, with response rates in prior clincical trials ranging from 7-15%. This contributes to poor patient outcomes, as ovarian cancer is currently the fifth leading cause of cancer death among women.Murine ovarian cancer study results: Substantial survival effect of the combination therapy (AllocetraTM + anti-PD1 immune checkpoint inhibitor), with up to 50% survival probability vs. 0% in the untreated group, and a highly significant 83% increase in survival durationComparable and strong effect in survival duration with stand-alone anti-PD1 and stand-alone Allocetra™ treatments (42% and 58% increase, respectively), and no significant effect on survival probability. Study conducted in collaboration with Yale Cancer Center These results, together with prior preclinical data in mesothelioma cancer, demonstrate Allocetra’s broadly applicable immunotherapeutic effects and its potential to deliver survival benefits across multiple solid cancers when combined with various immune checkpoint inhibitors. Nes-Ziona, Israel, May 31, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced new preclinical data from an ovarian cancer study conducted in collaboration with Yale Cancer Center. The study showed substantial and statistically significant improvements in survival benefit, survival duration and tumor burden reduction when Allocetra™ was combined with an anti-PD1 checkpoint inhibitor. The data will be featured in an upcoming poster presentation at the ASCO Annual Meeting, which is taking place both virtually and in-person at the McCormick Place convention center in Chicago, Illinois (United States) from June 3 – 7, 2022. The upcoming ASCO poster will also highlight a prior preclinical study in mesothelioma cancer that showed a substantial survival benefit when Allocetra™ was combined with a commercially approved anti-CTLA4 checkpoint inhibitor. Previously reported preclinical data in peritoneal cancer that show a substantial survival benefit when Allocetra™ is combined with chimeric antigen receptor (CAR) T-cell therapy will also be presented. Marcus Bosenberg, MD, PhD, Professor of Dermatology, Pathology, and Immunobiology and Director o...